116 results about "Liquid oral" patented technology

A method of treating gastric acid disorders by administering to a patient a pharmaceutical composition comprising a proton pump inhibitor (PPI) in a pharmaceutically acceptable carrier.

The present invention provides an oral solution/suspension comprising a proton pump inhibitor and at least one buffering agent. The PPI can be any substituted benzimidazole compound having H⁺,K⁺-ATPase inhibiting activity and being unstable to acid. Omeprazole and lansoprazole are the preferred PPIs for use in oral suspensions in concentrations of at least greater than 1.2 mg/ml and 0.3 mg, respectively. The liquid oral compositions can be further comprised of parietal cell activators, anti-foaming agents and/or flavoring agents. The inventive compositions can alternatively be formulated as a powder, tablet, suspension tablet, chewable tablet, capsule, effervescent powder, effervescent tablet, pellets and granules. Such dosage forms are advantageously devoid of any enteric coating or delayed or sustained-release delivery mechanisms, and comprise a PPI and at least one buffering agent to protect the PPI against acid degradation. Similar to the liquid dosage form, the dry forms can further include anti-foaming agents, parietal cell activators and flavoring agents. Kits utilizing the inventive dry dosage forms are also disclosed herein to provide for the easy preparation of a liquid composition from the dry forms. In accordance with the present invention, there is further provided a method of treating gastric acid disorders by administering to a patient a pharmaceutical composition comprising a proton pump inhibitor in a pharmaceutically acceptable carrier and at least one buffering agent wherein the administering step comprises providing a patient with a single dose of the composition without requiring further administering of the buffering agent. Additionally, the present invention relates to a method for enhancing the pharmacological activity of an intravenously administered proton pump inhibitor in which at least one parietal cell activator is orally administered to the patient before, during or after the intravenous administration of the proton pump inhibitor.

A liquid oral therapeutic dental composition, that increases in viscosity upon contact with moisture following application to an oral cavity surface, is disclosed. The composition comprises a moisture responsive gel carrier comprising a moisture sensitive polymer complex and a water soluble salt and a therapeutic agent dispersed in the responsive gel carrier. Methods and devices for administering the composition are also disclosed.

The invention discloses a preparation method of a functional oral preparation rich in erythrothioneine, which comprises the following steps: firstly, edible fungus mycelium rich in erythrothioneine is mixed with water, and under the temperature of 80 to 100 DEG C, the mixture is stirred and leached; secondly, a concentrated solution is obtained through concentration, and acceptable additives of food are added to the concentrated solution, so that the liquid oral preparation is obtained. The edible fungus mycelium rich in the erythrothioneine obtained by adopting a submerged fermentation biosynthesis method of the edible fungus mycelium is used as a raw material; and after treated by the process steps of the method, the obtained functional oral preparation, prepared from the concentrated solution or a dried material of the concentrated solution is high in product safety. The process provided by the invention has the advantages that all elements of the edible fungus mycelium rich in the erythrothioneine are comprehensively utilized; yield loss caused by extraction of functional elements through purification process is zero; the steps of the process are simple; the energy consumption is less; the erythrothioneine in the body of the mycelium is leached out of cells; and the usage efficiency of the erythrothioneine is high.

The oral cleaning appliance includes an assembly for generating low-pressure bursts of gas in the range of 2-7 bar, directed to a mixing chamber portion of the appliance. A pump provides successive doses of liquid to the mixing chamber. The mixing chamber includes an outlet for liquid droplets produced by the interaction of the gas and the liquid in the mixing chamber. The gas inlet line to the mixing chamber has an internal diameter in the range of 1 -5 mm. The center line of the gas inlet line is offset from the center line of the liquid droplet outlet line by a distance in the range of 1 -5 mm.

The invention relates to the application of effective component forsythin in preparation of tablet to swallow for curing adiposis and Health-care food. Forsythin is an effective component abstracted from fruit or leaf of Chinese medicine forsythia, it is mixed with organic or inorganic, solid or liquid excipient to form solid preparation to swallow such as tablet, capsule, particle, powder and pill, and it can also be added into food to produce Health-care food. The poisonous experiment has proved that the LD50 of rat is 8.30g/Kg, it has smaller poisonous side effect, and medicine effect experiment has proved that it can reduce the weight rate of growth, coefficients of fat and lee's index of nutritional fat rat, make the cell of fat rat become smaller by decreasing cholesterin and triglyceride content in serum, so it has better effect for nutritional fat rat.

The invention provides a liquid oral rehydration salt which comprises the following components in percentage by weight: 0.056-0.96% of sodium chloride, 0.034-0.042% of potassium chloride, 0.065-0.079% of sodium citrate, 0.31-0.37% of glucose and 94.5-104.5% of water. The liquid oral rehydration salt is used for treating mild and moderate dehydration caused by diarrhea and dehydration caused by children diarrhea. Through accurate control of water dosage, asepsis operation and other treatment, the high liquid oral rehydration salt is stable in quality, more convenient to use and suitable for being taken by old people and children under water shortage conditions in the open air and in case of an emergency, and can better express the efficacy.

The invention discloses a method for preparing panax japonicus saponin IVa and an application of panax japonicus saponin IVa in preparing a medicament for protecting liver and lowering transaminase. The preparation method mainly comprises the following steps: crushing panax japonicus saponin IVa bulk pharmaceutical chemicals, extracting with water or a hydrophilic organic solvent, filtering and concentrating extract; passing the concentrated solution through a macroporous adsorption resin column chromatography column so as to enrich total saponin, eluting with water and an alcohol-water mixedliquid in turn, collecting the alcohol-water eluent, performing reduced pressure concentration at a low temperature, and drying to obtain the total saponin; and carrying out chromatograph separation on the total saponin, eluting with a solvent, recovering the solvent at reduced pressure, and drying so as to obtain crude panax japonicus saponin IVa; and repeatedly recrystallizing the crude productwith an organic solvent so as to obtain pure panax japonicus saponin IVa. According to verification, the panax japonicus saponin IVa has bioactivity of protecting liver and lowering transaminase, andcan be mixed with one or more of pharmaceutically acceptable carriers/auxiliary materials so as to be prepared into solid and liquid oral preparations with effects of protecting liver and lowering transaminase.

The present invention discloses pharmaceutical compositions comprising of pH sensitive polymers used for taste masking highly bitter drugs. The pH sensitive polymer acts as a reverse enteric coating, which is soluble in the acidic pH range 1.0 to 3.0 normally found in the stomach but is insoluble in the pH range 3.5 to 7 thus inhibiting the release of the bitter drug at the pH of saliva and also at the pH of reconstitution medium in case of liquid orals.

A method of treating and/or preventing symptoms of Rett syndrome (RTT) in a patient such as a patient previously diagnosed with Rett syndrome, by administering an effective dose of a 5-HT_1D, 5-HT_2A, 5-HT_2C or sigma-1 receptor agonist (e.g., fenfluramine or its pharmaceutically acceptable salt) to that patient. RTT patients are treated at a preferred dose of less than about 1.0 mg/kg/day and may be administered as fenfluramine in an amount of between 0.2 to 0.8 mg/kg/day, to a maximum of 30 mg/day in a liquid oral dose.

The invention concerns nutritional compositions for persons with a (partially) functional gastrointestinal tract, who are unwilling and/or unable to consume sufficient quantities of conventional food to meet their nutritional requirements such as malnourished persons or persons at risk of becoming malnourished, and in need of liquid oral nutrition. The shelf-stable liquid nutritional compositions comprise at least non-micellar casein, a high amount of fat, and optionally a heat stabilisation system.

Oral liquid colchicine formulations are described herein. Methods of using the oral liquid colchicine formulations are also provided.

The invention provides a liquid oral composition containing TCM active substances and the tea tree essential oil. The liquid oral composition comprises the following materials in parts by weight: 1.0 to 10 parts of traditional Chinese medicine extracts, 0.1-6 parts of additives, 0.001-0.005 part of menthol, 0.001-0.006 part of tea tree essential oil, and 90-100 parts of water. The traditional Chinese medicine extracts are composed of green tea extract, affine cudweed extract, plantain herb extract, Lamium album extract, tea tree root extract, gallnut, honeysuckle and orange peel mixed extract, and violet extract. The additives are composed of a wetting agent, a pH regulator, a preservative, essence and a flocculating agent.

The invention discloses a chitosan oligosaccharide liquid oral administration preparation and a preparation method thereof. The oral administration preparation comprises chitosan oligosaccharide, hawcondensed juice, fructo-oligosaccharide, vitamin C, steviol glycoside, citric acid and water. The chitosan oligosaccharide liquid oral administration preparation disclosed by the invention has the effects of reducing blood sugar, reducing blood lipid and enhancing organism immunity after being drunk by normal people; and the preparation method of the chitosan oligosaccharide liquid oral administration preparation is simple, and the oral administration preparation prepared by the preparation method facilitates absorption by human bodies and is good in mouth feel.

Provided is a liquid oral composition which has an improved effect of preventing the adhesion of stain onto teeth, is free from a sensation of astringency or irritation, does not render the inside of an oral cavity sticky after being applied to the oral cavity, can leave a good sensation particularly after the washing of the mouth with the liquid oral composition, and has a highly clear preparation appearance. A liquid oral composition characterized by comprising (A) a condensed phosphoric acid salt, (B) a hydroxyalkyl cellulose, (C) an acylsarcosine salt and (D) a nonionic surfactant.

The invention belongs to the technical field of health-care foods, and particularly relates to a health-care food of a coenzyme Q10 liposome and a making method of the health-care food. The coenzyme Q10 liposome is a liquid orally-taken health-care product, coenzyme Q10, lecithin, cholesterol, tween-80 and VE acetate dissolve when being heated with ethanol, and reduction vaporization is performed,so that a smooth film is formed; after vacuum drying, polyvinylpyrrolidone and glycerine are added, an aqueous phase medium hydration film is added to obtain emulsifying liquid, and ultrasonic treatment is performed on the emulsifying liquid to obtain the coenzyme Q10 liposome of which the particle diameter is nanoscale, wherein the concentration of the coenzyme Q10 can achieve 30-40mg/mL. The coenzyme Q10 is packed in the liposome, so that the problem that the coenzyme Q10 liquid oral liquid is unstable can be solved, the bioavailability of the coenzyme Q10 in bodies can be reinforced, and the passive target action of the coenzyme Q10 is realized. The prepared coenzyme Q10 liposome has the effects of improving the immunity of human bodies, and increasing functions of resisting oxidation,delaying senescence, and the like.

Disclosed is a liquid oral composition that has excellent stability in appearance, is perceived to be mild and refreshing when used in the oral cavity, has an excellent lasting sensation of coolness and retention, and is non-ethanol-based. Further disclosed is a method for producing same. The liquid oral composition that contains virtually no ethanol is mixed with: (A) a polyoxyethylene-cured castor oil having an E.O. average added mole number of 40-100 moles; (B) an emulsion comprising a decaglycerol mono-fatty acid ester, a tri-fatty acid glyceryl, glycerol, and water, and having an average particle size of 50-500 nm; (C) L-menthol; (D) 3-(L-menthoxy) propane-1,2-diol; and (E) a polyvalent alcohol selected from glycerol, propylene glycol, and a polyethylene glycol that has an average molecular weight of 190-630. In the method for producing the abovementioned oral composition, after combining the abovementioned components A, C, D, and E, component B is added.

The invention relates to application of compounds, which are separated from ganoderma fungi and have alpha-glucosidase inhibiting activity, to medicinal treatment and functional food health care. The alpha-glucosidase inhibiting activity of the compounds or natural or synthetic components containing one or more of the compounds is 1.6-26 times of that of acarbose. The compounds or the components containing the compounds can be prepared into a variety of solid or liquid oral preparations, or through addition of other components and auxiliary materials, compound medicines or health products are prepared and are used for treating and preventing diabetes.

The invention provides ethanol-free liquid oral care compositions comprising cetyl pyridinium chloride which do not have an unacceptably bitter taste, e.g. mouthwashes, toothpastes, throat sprays, and breath sprays that are substantially free of ethanol, e.g., comprising (i) an antimicrobially effective amount of cetyl pyridinium chloride (CPC), (ii) one or more flavoring oils which are substantially insoluble in water at room temperature, and (iii) water, wherein the ratio of the CPC to the one or more flavoring oils is from 1:1.5 to 1:2.5, as well as methods of making and using the same.